Funding Rounds
Biofidelity

Biofidelity Series B (2024, $24M)

Biofidelity

Genomic technology developer to detect biomarkers for non-small cell lung cancer (NSCLC).

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $24.00M

Raised Date: 2024-03-01

Investors